Amgen Launches Direct-to-Patient Program for Repatha to Improve Access and Affordability

Amgen has announced the launch of AmgenNow, a direct-to-patient program aimed at providing access to its cardiovascular treatment, Repatha. The initiative is designed to make the medication more affordable and accessible for patients in need of life-saving therapies.

Repatha, a prescription drug used to lower cholesterol and reduce the risk of heart attack and stroke, is now available through this program directly to patients. AmgenNow seeks to streamline the process for obtaining the medication while addressing affordability concerns. The company has not disclosed specific details about pricing or eligibility criteria but emphasizes that the program aims to remove barriers that may prevent patients from accessing necessary treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 7, 2025

Related posts:

BCG Immunotherapy Found to Reprogram Bone Marrow for Enhanced Cancer-Fighting Immune Response Modified mRNA Vaccines Incorporating IL-12 Show Enhanced T Cell Activation FDA Releases White Paper on Selective Safety Data Collection for Late-Stage Clinical Trials United Imaging Intelligence Secures CE Marking for 18 Additional Medical AI Applications in July 2025

Author

Mark Chiang